分化型甲状腺癌术后放射性碘治疗诱发第二原发恶性肿瘤风险的研究进展  

Research progress on the risk of secondary primary malignancy induced by radioactive iodine therapy for postoperative differentiated thyroid cancer

作　　者：王宇鑫 姜楠 林秋玉[1] 赵爽言 王嘉文 林承赫[1] Wang Yuxin;Jiang Nan;Lin Qiuyu;Zhao Shuangyan;Wang Jiawen;Lin Chenghe(Department of Nuclear Medicine,the First Hospital of Jilin University,Changchun 130061,China)

机构地区：[1]吉林大学第一医院核医学科,长春130061

出　　处：《中华核医学与分子影像杂志》2024年第8期500-504,共5页Chinese Journal of Nuclear Medicine and Molecular Imaging

基　　金：国家自然科学基金(81901774)。

摘　　要：分化型甲状腺癌(DTC)的预后良好,10年生存率>90%。放射性碘(RAI)治疗属于辐射暴露,具有诱发恶性肿瘤的潜在可能。RAI治疗是否会导致第二原发恶性肿瘤(SPM)风险增高目前仍存在很大的争议。该文综述国内外相关研究的现状,并总结目前研究的局限性及未来研究需要注意的问题。目前尚无足够的临床证据证明RAI治疗会增加DTC术后患者的总体SPM风险。With good prognosis of differentiated thyroid cancer(DTC),the 10-year survival rate of DTC patients is more than 90%.As a kind of radiation exposure,radioactive iodine(RAI)treatment has the potential to induce malignancies.Based on this view,whether RAI treatment will increase the risk of secondary primary malignancy(SPM)still has a lot of controversy.This review summarizes current situation of related researches,and also summarizes the limitations of the current researches and the problems to be solved in the future research.In this review,it is believed that RAI treatment does not increase the overall risk of SPM in postoperative-DTC patients.

关 键 词：甲状腺肿瘤 放射疗法 碘放射性同位素 肿瘤 继发原发性 发展趋势 

分 类 号：R736.1[医药卫生—肿瘤]